An ANA test can detect antinuclear antibodies (ANA)
in your blood. Your immune system normally makes antibodies to fight an infection. However, some people also create antinuclear antibodies, which often times can attack your
body's own tissues.
Your doctor may say you need an ANA test to determine if you have an autoimmune disease, such as lupus, scleroderma or rheumatoid arthritis.
Prescription Drug User Fee Act (PDUFA) Reauthorization Process
The Prescription Drug User Fee Act (PDUFA) authorizes the U.S. Food and Drug Administration (FDA) to collect
fees from pharmaceutical companies to help fund the agency’s drug review
work. PDUFA’s intent is to provide additional funding for FDA to hire
staff, improve systems, and establish a better-managed review process
that enables us to do more timely reviews of human drug applications.
As a result, many important new drug therapies have been made available
to patients sooner without compromising FDA’s high standards for safety,
efficacy, and quality.
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.